Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Safety, Efficacy and Pharmacokinetics of VX-710 in Combination With Doxorubicin and Vincristine in Patients With Small Cell Lung Cancer (SCLC)

NCT00003847 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT00003847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Safety, Efficacy and Pharmacokinetics of VX-710 in Combination With Doxorubicin and Vincristine in Patients With Small Cell Lung Cancer (SCLC)
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 1998
Completion date
Not reported
Enrollment
36 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer